ROBIN PARIHAR to Neoplasms
This is a "connection" page, showing publications ROBIN PARIHAR has written about Neoplasms.
Connection Strength
0.486
-
NK Cell Therapeutics for Hematologic Malignancies: from Potential to Fruition. Curr Hematol Malig Rep. 2023 Dec; 18(6):264-272.
Score: 0.149
-
Detection of response to tumor microenvironment-targeted cellular immunotherapy using nano-radiomics. Sci Adv. 2020 07; 6(28):eaba6156.
Score: 0.119
-
Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. Adv Exp Med Biol. 2020; 1224:117-140.
Score: 0.115
-
Novel cytokines in the treatment of malignancies. Cancer Treat Res. 2005; 126:353-73.
Score: 0.041
-
A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients. Clin Cancer Res. 2004 Aug 01; 10(15):5027-37.
Score: 0.040
-
Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12. J Clin Oncol. 2005 Dec 01; 23(34):8835-44.
Score: 0.011
-
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin Cancer Res. 2002 Dec; 8(12):3718-27.
Score: 0.009
-
Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells. Cancer Res. 2006 Jan 01; 66(1):517-26.
Score: 0.003